New to Meducation?
Sign up
Already signed up? Log In

Category

Preview
17
323

Chemotherapy

Chemotherapy  
Stephen McAleer
over 6 years ago
4
5
91

Sepsis - Part 1

<div class="postBody">Sepsis is a common cause of death in the intensive care unit.&nbsp; In this episode I present some of the statistics on septic deaths, introduce the definitions, and present the basic science.&nbsp; Part 2 will cover fluid and drug therapy for septic shock.&nbsp; </div>  
Jeffrey S. Guy, MD, FACS
about 9 years ago
3
5
307

Corticosteroids Overview

Review of corticosteroids pathophysiology, pharmacology, and pharmacotherapy  
Dustie Sieg
over 3 years ago
8
3
48

Focus On: Thrombolytic Therapy in Acute Ischemic Stroke

Initial management of the stroke patient in the emergency department requires prompt evaluation and stabilization.  
American College Of Emergency Medicine
about 9 years ago
Preview
3
47

Apoptosis and the response to chemotherapy

Apoptosis and response to chemotherapy  
Stephen McAleer
over 6 years ago
Preview
3
31

Leukemia treatment

There are three main solutions to treat leukemia. Chemotherapy is a collection of drugs which target cells that rapidly multiply (a key characteristic in can...  
YouTube
over 5 years ago
2
2
25

Treating Lung Cancer: Past, Present, and Future (Video)

This slide presentation by Dr. Ramiswamy Govindan, medical oncologist at Washington University in St. Louis, offers a broad perspective on the history of treating cancer with chemotherapy, our current treatment approaches, and a preview of emerging technologies that are poised to become a more individualized way of treating cancer.  
Howard (Jack) West, MD
about 9 years ago
5
2
30

Cancer Lifeline Lecture - Part 2, Adjuvant Chemo for Early Stage NSCLC (Audio)

This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he discusses the evidence supporting the current standard of adjuvant (post-operative) chemotherapy to improve survival for patients with early stage, resected NSCLC.  
Howard (Jack) West, MD
about 9 years ago
Preview
2
24

Molecular Pathology of Lung Cancer

As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.  
Google Books
over 4 years ago
Www.bmj
2
72

Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity

Polypharmacy, defined as the chronic co-prescription of several drugs, is often the consequence of the application of disease specific guidelines, targeting disease specific goals, to patients with multiple chronic diseases. One common consequence of polypharmacy is the high rate of adverse drug reactions, mainly from drug-drug interactions (the ability of a drug to modify the action or effect of another drug administered successively or simultaneously).1 The risk of a drug-drug interaction in any particular patient increases with the number of co-existing diseases and the number of drugs prescribed.2  
bmj.com
over 4 years ago
Preview
2
9

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment | Key-points-from-the-evidence | Advice | NICE

One large (n=1528), open-label, randomised controlled trial (RCT; ICON7) that assessed the efficacy and safety of bevacizumab 7.5 mg/kg for treating ovarian cancer was identified; quality of life outcomes from this study were also reported separately (Stark et al. 2013). ICON7 found that interim analysis of overall survival data showed no benefit for adding bevacizumab to standard chemotherapy compared with standard chemotherapy alone, except in a subgroup deemed at high risk for progression. In this subgroup median results for progression-free survival after a median follow-up of 19 months were 10.5 months with standard chemotherapy and 15.9 months with standard chemotherapy plus bevacizumab. Adding bevacizumab to standard chemotherapy resulted in a small but clinically relevant reduction in quality of life.  
nice.org.uk
almost 4 years ago
11
1
26

Polypharmacy in the Elderly

Patients are often admitted to the ICU with an entire list of home medications.&nbsp;&nbsp; In this episode I talk about the implications and dangers of polypharmacy.&nbsp;  
Jeffrey S. Guy, MD, FACS
about 9 years ago
5
1
29

Q&A on Post-Operative Chemotherapy for Head/Neck Cancer, by Dr. Ezra Cohen (audio)

<p>Q&amp;A session wtih Dr. Ezra Cohen, medical oncologist from the University of Chicago, after his expert overview of head/neck cancer and specific discussion of role of post-operative chemotherapy.</p>  
Howard (Jack) West, MD
about 9 years ago
6
1
31

Q&A on Post-Operative Chemotherapy for Head/Neck Cancer, by Dr. Ezra Cohen (video)

<p>Q&amp;A session wtih Dr. Ezra Cohen, medical oncologist from the University of Chicago, after his expert overview of head/neck cancer and specific discussion of role of post-operative chemotherapy.</p>  
Howard (Jack) West, MD
about 9 years ago
7
1
35

Post-Operative Chemotherapy for Head/Neck Cancer, by Dr. Ezra Cohen (audio)

<p>Dr. Ezra Cohen, medical oncologist from the University of Chicago, provides expert overview of head/neck cancer and specific discussion of role of post-operative chemotherapy.</p>  
Howard (Jack) West, MD
about 9 years ago
8
1
45

Post-Operative Chemotherapy for Head/Neck Cancer, by Dr. Ezra Cohen (video)

<p>Dr. Ezra Cohen, medical oncologist from the University of Chicago, provides expert overview of head/neck cancer and specific discussion of role of post-operative chemotherapy.</p>  
Howard (Jack) West, MD
about 9 years ago
11
1
29

Case Discussion with Experts, Drs. Julie Brahmer and Greg Riely: Case 1 (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.</span></p>  
Howard (Jack) West, MD
about 9 years ago
12
1
23

Case Discussion with Experts, Drs. Julie Brahmer and Greg Riely: Case 1 (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.</span></p>  
Howard (Jack) West, MD
about 9 years ago
1
1
26

Treating Lung Cancer: Past, Present, and Future (Audio)

This slide presentation by Dr. Ramiswamy Govindan, medical oncologist at Washington University in St. Louis, offers a broad perspective on the history of treating cancer with chemotherapy, our current treatment approaches, and a preview of emerging technologies that are poised to become a more individualized way of treating cancer.  
Howard (Jack) West, MD
about 9 years ago